Stocksigma LogoStocksigma Logo

SPARC Reports Zero Deviation in Preferential Issue Utilization for Q2 FY26-27

Acuité Ratings & Research issued a clean Monitoring Agency Report for Sun Pharma Advanced Research Company Ltd

SPARC Reports Zero Deviation in Preferential Issue Utilization for Q2 FY26-27

Sun Pharma Advanced Research Company Ltd · Others (Uncategorized) · 03 Nov 2026, 1:41 am

SPARC Reports Zero Deviation in Preferential Issue Utilization for Q2 FY26-27 Acuité Ratings & Research issued a clean Monitoring Agency Report for Sun Pharma Advanced Research Company Ltd. for the quarter ended 30th Sep'26, confirming zero deviation from stated objects. Out of the total ₹599.98 Cr preferential warrant issue, ₹150.00 Cr raised earlier was fully utilized toward working capital loan repayment during Q1 FY26-27. No additional warrants were subscribed or funds received during Q2 FY26-27, leaving zero additional utilization during the quarter across R&D clinical trial activities (₹300.00 Cr allocated) and general corporate purposes (₹149.98 Cr allocated).

Original exchange filing (PDF)

More announcements from Sun Pharma Advanced Research Company Ltd

All Sun Pharma Advanced Research Company Ltd announcements